Merger Plan of €3 Billion Chemical Giant Hangs in the Balance, OMV Internal Disputes Intensify!
According to reliable sources, the planned multi-billion euro chemical industry merger between Borealis, a subsidiary of Austrian oil company OMV, and Borouge, an ABU Dhabi company, is facing major challenges. The merger plan aims to create a global leader in the chemical industry from scratch. If the merger plan is not successful, it will have a certain negative impact on OMV.
After a long period of intensive research and careful planning, OMV's negotiating team is working to advance a historic industrial deal that will undoubtedly leave a deep mark in China's economic history. The opponents involved in the negotiations are strong international partners. OMV is currently engaged in intense but orderly negotiations with ADNOC, the ABU Dhabi-based state holding company, over a joint venture between its chemicals division and the much larger Borouge with Borealis, a subsidiary of OMV. Once the negotiations are successful, a giant enterprise will be born in the forefront of the chemical industry in the world.
Since its inception, the project has faced a number of serious challenges relating to the true ownership structure, the distribution of voting rights and detailed rules for Arab owners. At the same time, the economic price OMV is reportedly paying for equal status has risen significantly. Courier-daily quoted an offer of up to €3 billion, which OMV has categorically denied. OMV's chief financial officer Reinhard Florey is negotiating on behalf of the Austrian side, but has hit a snag in the process with Adnoc manager Khaled Salmeen. The two men also disagree on other matters: Florey and Salmeen, who are members of the executive board, and Khaled Al Zaabi, chief financial officer of ABU Dhabi National Oil Company, have opposing interests as representatives of Adnoc's owners on OMV's supervisory board. The internally appointed ABU Dhabi co-owner currently holds 24.9% of OMV.
Harmony on the OMV supervisory Board has never really seemed to be achieved in the long history, and the recent situation has been particularly severe. News of the impending departure of Daniela Vlad, a new member of OMV Chemicals' board of directors, has been widely reported in the media, citing a lack of depth of expertise as the reason.
In the elite circles of Austrian economics, the event was seen as an unprecedented low point. Throughout, OMV's older managers have disagreed with the strategy of partially abandoning its traditional oil business and moving into chemicals, and saw the partnership with Borealis as a strategic highlight. Even under the leadership of Alfred Stern, the chief executive, who was fiercely defensive, internal opposition was never fully quelled.
If the proposed merger of the two chemical giants were to fail, it would not only miss an important opportunity for Austria's flagship company, but would also likely create a deep rift among OMV's many owners, including the Republic, thousands of shareholders, sovereign wealth funds and the Sultanate family of the United Arab Emirates.
2026-08-10
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Symrise Opens New Production Unit in Granada to Ensure Safer Supply of Bio-Based Pentylene Glycol
-
Mitsubishi Gas Chemical Suspends Construction of MXDA Plant in the Netherlands
-
NHU and Sinopec Advance Liquid Methionine Project
-
BASF and Nihon Nohyaku Partner for Fruit Crop Protection in Japan
-
Doré Partners with Evolved By Nature to Launch Two Breakthrough Skincare Products
-
When the Chemical Industry Is No Longer Highly Profitable: Sinochem International’s 2.4 Billion Yuan Loss Reveals the Truth About Industry Cycles
-
AstraZeneca Targets Year-End Filing for Novel Hypertension Drug Baxdrostat
-
Brenntag Expands Distribution of Givaudan’s Active Beauty Ingredients to Malaysia and Singapore
-
Avery Dennison to Acquire Meridian’s Flooring Adhesives Business for $390 Million
-
Aurobindo Pharma’s $145 Million China Plant Set to Break Even by Q3 FY26 Global Expansion Gains Speed
Recommend Reading
-
Bayer’s Ambitious Gene & Cell Therapy Pipeline Eyes Parkinson’s, Oncology, Rare Diseases
-
Syngenta’s VIRESTINA Targets Resistant Weeds as Herbicide Innovation Regains Urgency
-
Brazil’s SISPA Platform Signals a New Phase in Pesticide Registration
-
Bristol Myers Squibb Launches Mavacamten (“Kopozgo”) in India for Obstructive Hypertrophic Cardiomyopathy
-
BASF’s Price Increase Shows Pharma Excipients Are Still Exposed to Chemical Cost Pressure
-
Early September Acetic Acid Market Remains Strong
-
Chinese Hydrofluoric Acid Market Shows a Steady and Slightly Strong Trend
-
FDA’s Warning to Compounders Raises the Stakes for API and Excipient Suppliers
-
Limited Positive Factors Drive Downward Trend in Shandong Butanol Prices in Early September
-
EU Biocidal Data Protection Extension Raises the Stakes for Chemical Market Entry
- Hot Searches
- glp 3 retatrutide where to buy
- sodium hydroxide supplier
- amoxycillin and potassium clavulanate tablets
- polyvinyl chloride price
- bulk acetic acid
- red 167
- reta for sale
- sodium potassium mag sulfates 17.5 gram-3.13 gram-1.6 gram oral solution
- myclobutanil market
- aluminum chloride
- buy steroid
- methylamine price per gallon